“To our knowledge, we’re the only ones with a clinical Phase 2-ready molecule targeting PGC-1α. Big pharma recognizes it as a target of interest, but we’re a small company – we won’t change the paradigm by talking about it; we’ll change it by showing clinical data.”
1 Like